NCT01049815View on ClinicalTrials.gov

Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

NACompletedINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

End Stage Renal DiseaseHemodialysisIntimal Media Thickness

Interventions

DRUG

sevelamer hydrochloride

800-3200 mg with each meal

DRUG

Calcium Carbonate

600 mg with each meal, up to 1800 mg a day

Trial Locations (2)

Unknown

Edith Wolfson Medical Center, Holon

Tel Aviv Medical Center, Tel Aviv

All Listed Sponsors

collaborator

Wolfson Medical Center

OTHER_GOV

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV

NCT01049815 - Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease | Biotech Hunter | Biotech Hunter